Entering text into the input field will update the search result below

Progenity sets IPO terms

  • Progenity (PROG) has filed a prospectus for its IPO of ~6.7M common shares at $14 - 16 per share. Gross proceeds should be ~$100M (midpoint).
  • The molecular testing services provider's lineup consists of a non-invasive prenatal test for fetal chromosomal disorders, an expanded carrier screen (preconception or early in pregnancy) for genetic diseases, a hereditary cancer screen, a prenatal test for monogenic disease and a portfolio of anatomic and molecular pathology tests.
  • Selected competitors: LabCorp (NYSE:LH), Quest Diagnostics (NYSE:DGX), Natera (NASDAQ:NTRA), Myriad Genetics (NASDAQ:MYGN), Invitae (NYSE:NVTA)
  • Progenity on deck for IPO

Recommended For You

Related Stocks

SymbolLast Price% Chg
BIOR--
Biora Therapeutics, Inc.
LH--
Laboratory Corporation of America Holdings
DGX--
Quest Diagnostics Incorporated
NTRA--
Natera, Inc.
MYGN--
Myriad Genetics, Inc.